Company: DAWN
Filing Date: 2025-04-11
Form Type: DEF 14A
Source: 0001140361-25-013462
Chunk: 24

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-04-11
Form: DEF 14A
Chunk 24
---
 Director                  |     | Age |     | Position |     | Director Since |
| Class II Directors:               |     |     |     |          |     |                |
| Scott Garland(1)                  |     |  56 |     | Director |     | August 2021    |
| William Grossman(2)               |     |  55 |     | Director |     | January 2024   |
| John Josey, Ph.D., M.B.A.(3)      |     |  64 |     | Director |     | September 2020 |
| Class III Directors:              |     |     |     |          |     |                |
| Jeremy Bender, Ph.D., M.B.A.      |     |  53 |     | Director |     | September 2020 |
| Habib Dable, M.B.A.(3)            |     |  55 |     | Director |     | January 2024   |
| Saira Ramasastry, M.S., M.Phil(1) |     |  49 |     | Director |     | March 2021     |

| (1) | Member of the audit committee. |

| (2) | Member of the compensation committee. |

| (3) | Member of the nominating and corporate governance committee. |

Scott Garland has served as a member of our board of directors since August 2021. Scott was Chief Executive Officer of PACT Pharma, an immune-oncology company, from March 2021 to February 2023. Prior to joining PACT, Mr. Garland was President, CEO and a member of the board of Portola Pharmaceuticals prior to its merger with Alexion Pharmaceuticals, Inc. in July 2020. Prior to Portola, Mr. Garland served as President of Relypsa Inc., a biopharmaceutical company, from April 2017 to October 2018, and as Senior Vice President and Chief Commercial Officer from November 2014 to April 2017. From October 2011 to October 2014, Mr. Garland served as Executive Vice President and Chief Commercial Officer of Exelixis, Inc., a biopharmaceutical company focused on developing and commercializing cancer treatments. From April 2002 to October 2011, Mr. Garland held positions at Genentech, Inc., a biopharmaceutical company, most recently serving as Vice President of Genentech’s Avastin® franchise, where